Teleflex Incorporated (TFX), has had various key developments lately. Despite some operational hiccups, the company's Urolift installation has demonstrated consistent growth, although organic sales were hit by the pandemic. Teleflex also reported a series of earnings calls, including Q1, Q2, Q3, and Q4 2023, and Q1 2024. In recent movements,
Russell Investments Group Ltd,
Amalgamated Bank,
Truist Financial Corp, and
Swiss National Bank have decreased their stake in TFX, while
Natixis Advisors L.P and
New York Life Investment Management LLC have increased their stakes. Important developments include the unveiling of the
Arrow™ EZ-IO™ Intraosseous Access Procedure Tray and announcing the limited market release of the
Wattson™ Temporary Pacing Guidewire, the completed acquisition of
Palette Life Sciences, boosting its urology portfolio. They also received FDA approval for their Arrow EZ-IO needle. Even amidst mixed shareholder returns and
shrinking earnings, the company's Q1 and Q4 earnings beat estimates while Q2 and Q1 earnings compared with key metrics. The annual financial results are expected to be discussed soon.
Teleflex Incorporated TFX News Analytics from Tue, 29 Oct 2013 07:00:00 GMT to Sat, 11 May 2024 22:51:30 GMT -
Rating 3
- Innovation -4
- Information 7
- Rumor -5
